Coeptis Therapeutics Holdings Inc. (NASDAQ COEP)

Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics

Proposed transaction would provide Coeptis with two clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML) and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors.

About admin

Check Also

Italian Food and Beverage (OTC: IFBC) Accelerates Company Growth

PLAINVIEW, NY / ACCESSWIRE / October 11, 2022 / Italian Food & Beverage Corp. (OTC:IFBC): Further …